Nektar Erases $1.8 Billion of Value on Doubts Over Its Cancer Drug

(Bloomberg) -- Investors sentiment on Nektar Therapeutics has soured as a manufacturing snafu raised concern about what had initially been seen as promising clinical data for its experimental cance...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.